Hypomethylating agents (HMAs) are the standard of care for patients with myelodysplastic syndrome (MDS). However, only around 50% of patients respond to these agents, and responses tend to be transient, with loss of response frequently happening within 2 years and being associated with very poor prognosis and limited therapeutic options. Identification of patients who will respond to HMAs is challenging. Mechanisms underlying resistance to HMAs are not clear yet.
Thank you for attending the 2019 Patient & Family Conference in Rockville, Maryland.
If you are interested in learning more about your possible participation in this clinical trial, please complete the form. Your information will be forwarded directly to the sponsoring company.
This PDQ cancer information summary has current information about the treatment of
Immunosuppressive therapy is one therapy option for treatment of patients with lower-risk
Myeloid neoplasms, including
A patient with a diagnosis of myelodysplastic syndrome (MDS) with isolated 5q deletion underwent repeat